Breaking News

Corealis CDMO Completes Deal with ArchiMed

Significant recapitalization of Corealis will accelerate growth, including the build-out of state-of-the-art labs and GMP-compliant facilities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Private equity healthcare specialist ArchiMed is the lead investor in an alliance recapitalizing Corealis Pharma. ArchiMed and fellow investor, the Caisse de dépôt et placement de Québec, a pension fund in Canada, are joining forces with founders and management through this recapitalization. The partnership will further expand the drug development services Corealis offers as a Contract Development and Manufacturing Organization to small and medium-sized biotech and pharma companies.    Based i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters